Klus Pharma

KLUS Pharma is a U.S.-based biotech subsidiary of China's Kelun-Biotech, leveraging its parent company's integrated R&D and manufacturing platforms to advance a diverse pipeline of oncology and non-oncology biologics. The company has built a robust pipeline with multiple clinical-stage assets, most notably in the competitive ADC space, including TROP2 and HER2-targeting candidates. Its strategy combines internal development with strategic partnerships, such as the recent collaboration with Crescent Biopharma, to maximize the global value of its pipeline. KLUS operates as a key bridge for Kelun-Biotech's ambitions in the U.S. and international markets.

Integrated biologics discovery and development platform encompassing target discovery, antibody generation (hybridoma, phage display, yeast display), antibody engineering (humanization, Fc engineering, bispecifics), and a proprietary third-generation ADC platform for site-specific conjugation with tunable DAR. Supported by in-house GMP manufacturing.

KLUS's ADC programs face intense competition from established players (e.g., AstraZeneca/Daiichi Sankyo in HER2, Gilead in TROP2) and a crowded field of biotech innovators. Differentiation will require demonstrating superior clinical profiles. Its integrated platform competes with other biotechs and large pharma with internal ADC capabilities.